Podcast

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

Author(s):

Dr D’Amato discusses research in sarcoma and gastrointestinal stromal tumor, incorporating circulating tumor DNA analysis into routine reevaluation of patients with progressive disease, and the importance of establishing a drug’s clinical profile in non–trial target ethnic populations.

Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Deciphera Pharmaceuticals, we had the pleasure of speaking with Gina Z. D’Amato, MD, to discuss research in sarcoma and gastrointestinal stromal tumor that was presented at the 2022 ASCO Annual Meeting, 2023 Gastrointestinal Cancers Symposium, and 2023 January ASCO Plenary Series.

Dr D’Amato is an associate professor of medicine and sarcoma medical oncology and the assistant director of clinical research at Sylvester Comprehensive Cancer Center, part of the University of Miami Health System in Florida.

In our exclusive interview, Dr D’Amato discussed the significance of incorporating circulating tumor DNA analysis into routine reevaluation of patients with progressive disease, emphasized the importance of establishing a drug’s clinical profile in non–trial target ethnic populations, and highlighted a first-in-human trial evaluating IDRX-42, a novel TKI that could overcome acquired resistance to standard therapy. 

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Deciphera Pharmaceuticals. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Janaki Neela Sharma, MD
Justin M. Watts, MD
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Janaki Neela Sharma, MD, University of Miami
Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Janaki Neela Sharma, MD